Immune-related Neurological Symptoms in an Adolescent Patient Receiving the Checkpoint Inhibitor Nivolumab

Journal of Immunotherapy

Volumn 40, Issue 7, 2017, Pages 286-288

  Tchapyjnikov, Dmitry ^a   Borst, Alexandra J ^b  

^a Division of Neurology   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

autoimmune; checkpoint inhibitor; Hodgkin lymphoma; immunotherapy; neurologic; nivolumab

Indexed keywords

ANTIHYPERTENSIVE AGENT; BACLOFEN; DIAZEPAM; GABAPENTIN; IMMUNOGLOBULIN; LEVETIRACETAM; LEVOTHYROXINE SODIUM; LORAZEPAM; METHYLPREDNISOLONE; NIVOLUMAB; BIOLOGICAL MARKER; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BABINSKI REFLEX; BLOOD CELL COUNT; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; CLINICAL ARTICLE; CLONUS; CORTICOSTEROID THERAPY; DRUG MEGADOSE; DYSPHAGIA; ELECTROENCEPHALOGRAPHY; FALLING; HASHIMOTO DISEASE; HODGKIN DISEASE; HOSPITAL READMISSION; HUMAN; HYPERREFLEXIA; HYPERTRANSAMINASEMIA; HYPONATREMIA; HYPOTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INDWELLING CATHETER; LEUKOCYTOSIS; LUMBAR PUNCTURE; LYMPH NODE IRRADIATION; MALE; MENTAL HEALTH; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA EXCHANGE; PLASMAPHERESIS; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSIVE ENCEPHALOMYELITIS WITH RIGIDITY AND MYOCLONUS; SEIZURE; SPASTICITY; STIFF MAN SYNDROME; THYROID FUNCTION; TONIC CLONIC SEIZURE; TREATMENT RESPONSE; URINE RETENTION; WALKING DIFFICULTY; YOUNG ADULT; ADOLESCENT; COMPLICATION; PROCEDURES; SYMPTOM ASSESSMENT; TREATMENT OUTCOME;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; BIOMARKERS; HODGKIN DISEASE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MALE; NERVOUS SYSTEM DISEASES; PLASMAPHERESIS; SYMPTOM ASSESSMENT; TREATMENT OUTCOME;

EID: 85020743444     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000177     Document Type: Article

References (25)

1. Marrone KA, Ying W, Naidoo J. Immune-related adverse events from immune checkpoint inhibitors. Clin Pharmacol Ther. 2016;100:242-251.
2. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkins lymphoma. N Engl J Med. 2015;372:311-319.
3. Turner MR, Irani SR, Leite MI, et al. Progressive encephalomyelitis with rigidity and myoclonus: glycine and NMDA receptor antibodies. Neurology. 2011;77:439-443.
4. Hadavi S, Noyce AJ, Leslie RD, et al. Stiff person syndrome. Pract Neurol. 2011;11:272-282.
5. Carvajal-Gonzalez A, LeiteMI, Waters P, et al. Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain. 2014;137(Pt 8):2178-2192.
6. Hutchinson M, Waters P, McHugh J, et al. Progressive encephalomyelitis, rigidity, and myoclonus: A novel glycine receptor antibody. Neurology. 2008;71:1291-1292.
7. Ueno S, Miyamoto N, Shimura H, et al. Successful immune moderation treatment for progressive encephalomyelitis with rigidity and myoclonus. Intern Med. 2015;54:219-221.
8. McKeon A, Robinson MT, McEvoy KM, et al. Stiff-man syndrome and variants: clinical course, treatments, and outcomes. Arch Neurol. 2012;69:230-238.
9. Stayer C, Tronnier V, Dressnandt J, et al. Intrathecal baclofen therapy for stiff-man syndrome and progressive encephalomyelopathy with rigidity and myoclonus. Neurology. 1997;49:1591-1597.
10. Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015;14:914-925.
11. Hobson EV, Craven I, Blank SC. Posterior reversible encephalopathy syndrome: A truly treatable neurologic illness. Perit Dial Int. 2012;32:590-594.
12. LaPorte J, Solh M, Ouanounou S. Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkins lymphoma. J Oncol Pharm Pract. 2015;23:71-74.
13. Hottinger AF. Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol. 2016;29:806-812.
14. Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann Oncol. 2011;22:991-993.
15. Maur M, Tomasello C, Frassoldati A, et al. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol. 2012;30:e76-e78.
16. Liao B, Shroff S, Kamiya-Matsuoka C, et al. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-Oncol. 2014;16:589-593.
17. Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:210-225.
18. Chang E, Sabichi AL, Sada YH. Myasthenia gravis after nivolumab therapy for squamous cell carcinoma of the bladder. J Immunother. 2017;40:114-116.
19. Kimura T, Fukushima S, Miyashita A, et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci. 2016;107:1055-1058.
20. Loochtan AI, Nickolich MS, Hobson-Webb LD. Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve. 2015; 52:307-308.
21. Polat P, Donofrio PD. Myasthenia gravis induced by nivolumab therapy in a patient with non-small-cell lung cancer. Muscle Nerve. 2016;54:507.
22. Sciacca G, Nicoletti A, Rampello L, et al. Benign form of myasthenia gravis after nivolumab treatment. Muscle Nerve. 2016;54:507-509.
23. Shirai T, Sano T, Kamijo F, et al. Acetylcholine receptor binding antibody-Associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol. 2016;46:86-88.
24. Williams TJ, Benavides DR, Patrice KA, et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol. 2016;73:928-933.
25. Tanaka R, Maruyama H, Tomidokoro Y, et al. Nivolumabinduced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barre syndrome: A case report. Jpn J Clin Oncol. 2016;46:875-878.